More drugmakers are expanding access in poorer countries, but progress continues to lag overall

The article covers the Index’s analysis of how companies responded to the COVID-19 pandemic and the opportunities to improve access to medicine in low- and middle-income countries.

“Covid should be a springboard. And I wish it was a turning point, but I fear it’s not," Access to Medicine Foundation CEO Jayasree K. Iyer tells the publication.

In the article, Silverman highlights where companies are stepping up, including the Index's finding that all 20 companies in scope of the Index now have an access-to-medicine strategy. The publication also covers areas where companies are falling short, including the low number of technology transfers for COVID-19 products covered by voluntary licences.

Read the full article on the statnews website.